In conclusion, the present study demonstrated that semaglutide promoted the proliferation and osteogenic differentiation of BMSCs through the Wnt/LRP5/β-catenin signaling pathway, and proved that LRP5 may be a key factor in GLP-1 promoting osteogenesis, which has certain positive implications for improving BMSCs function in OP patients with T2DM. The gene discussed is LRP5; the disease is type 2 diabetes mellitus.